Occam Recruits Former FDA Commissioner to Faeth Therapeutics
In November 2024, Occam Global recruited Stephen M. Hahn, M.D., to the board of Faeth Therapeutics. Hahn is a CEO-Partner of Flagship Pioneering and Chief Executive Officer of Harbinger Health.
Steve brings two decades of illustrious leadership in healthcare strategy, oncology, and translational/clinical research to this role. From 2019 to 2021, he served as the 24th U.S. Food and Drug Administration (FDA) Commissioner, overseeing COVID and non-COVID regulatory affairs, including therapeutics and vaccine development, devices, diagnostics, and clinical trials.
Before his appointment to the FDA, Steve held the positions of Chief Medical Executive and Chief Operating Officer at the prestigious MD Anderson Cancer Center in Houston, Texas. Prior to his executive roles at MD Anderson, he also led the Perelman School of Medicine radiation oncology department at the University of Pennsylvania.
Steve earned his M.D. from Temple University and his B.A. in Biology from Rice University.
About Faeth Therapeutics
Faeth Therapeutics focuses on developing cancer treatments by targeting the unique metabolic dependencies of cancer cells. Using insights from computational biology and machine learning, they analyze the specific metabolic pathways that fuel tumor growth. This approach allows Faeth to design therapies that disrupt multiple key metabolic points within cancer cells, aiming to weaken or eliminate their ability to proliferate.
In addition to their scientific innovation, Faeth offers a patient-centric experience through their app, which helps patients adhere to treatment protocols by customizing their nutritional and metabolic support. Their clinical trials incorporate this targeted metabolic approach, providing patients with personalized guidance to maximize the effectiveness of these therapies. This approach represents a shift in oncology by addressing cancer metabolism as a means to improve treatment outcomes.
Explore how we’ve helped life science organizations build exceptional executive leadership through our case studies.
Recent Placements
- Elaine Sun on the Board of Dynavax
- Gary Glick as Chairman at CHARM Therapeutics
- Ellen Lubman as CBO at Werewolf
- Dawn de los Santos as VP of People at Vestaron
- Dan Marquess as CSO at Vicinitas Therapeutics
- Wall Street Dynamo and Luminary Leader as CFO at Beam Therapeutics
- Ann Taylor to the Board of Unlearn
Occam Global is a leading executive search and advisory partner for entrepreneurs, investors, and corporations targeting exceptional goals across the life sciences, deep tech, and venture capital sectors worldwide. Since 2012, Occam has collaborated with top founders, CEOs, and investors across the tech industry to provide high-performing leaders who fuel growth. From stealth startups to public markets, we recruit senior executives, advise on organizational strategies, and invest alongside visionary teams to build innovative companies. Occam’s success is rooted in our proven ability to attract outstanding business and scientific leaders, seamless access to rare talent, and a strong commitment to results guided by high ethics and enlightened aggression. Whether you’re launching, leading, or investing, we are here to support growth through the power of talent.